TipRanks
Amn Healthcare Services Inc (AMN)
NYSE:AMN
Want to see AMN full AI Analyst Report?

AMN Healthcare Services (AMN) AI Stock Analysis

546 Followers

Top Page

AMN

AMN Healthcare Services

(NYSE:AMN)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - Gpt-5.6Sol)
Rating:53Neutral
Price Target:
$41.00
▲(20.91% Upside)
Action:Reiterated
Date:08/07/26
AMN scores in the mid-range primarily due to improving but still volatile fundamentals (profitability recovery and solid cash generation tempered by multi-year margin/revenue swings and meaningful debt) and a constructive-but-conservative earnings outlook that embeds normalization after nonrecurring Q2 benefits. The score is pulled down by weak near-term technical signals (below key short-term moving averages with subdued RSI/Stoch) and limited valuation support given the negative P/E and no dividend yield data.
Positive Factors
Strong cash generation
AMN is currently converting reported earnings into substantial operating and free cash flow, providing internal funding for debt service, technology investment, acquisitions, and working capital. This cash-generation capability improves resilience while the staffing cycle normalizes.
Negative Factors
Volatile and compressed profitability
The earnings rebound has not restored historical profitability, and the recent sequence of revenue declines and losses shows meaningful cyclicality. Lower margins leave less buffer against pricing or volume pressure and make durable earnings power harder to establish.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
AMN is currently converting reported earnings into substantial operating and free cash flow, providing internal funding for debt service, technology investment, acquisitions, and working capital. This cash-generation capability improves resilience while the staffing cycle normalizes.
Read all positive factors

AMN Healthcare Services Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Shows how much revenue each business line generates—travel nursing, permanent placement, locum tenens, and workforce solutions—revealing which parts of AMN drive growth, where margins may differ, and how vulnerable the company is to shifts in demand or reimbursement in specific healthcare staffing markets.
Chart InsightsAMN’s revenue mix is very lumpy: Nurse & Allied is driven by episodic labor‑disruption events (recent Q1 spike confirms this reliance) while its ex‑event volumes show modest underlying growth; Physician & Leadership is steady but trending lower from pricing and channel pressures; Technology & Workforce is in a persistent downtrend despite management’s AI/product investments, suggesting monetization lags. Management’s conservative guidance and client deposit refunds imply near‑term normalization of revenue and cash, so upside hinges on durable demand recovery and successful tech monetization, not repeat event revenue.
Data provided by:The Fly

AMN Healthcare Services (AMN) vs. SPDR S&P 500 ETF (SPY)

AMN Healthcare Services Business Overview & Revenue Model

Company Description
AMN Healthcare Services, Inc. (AMN) specializes in delivering comprehensive workforce solutions and staffing services to hospitals and healthcare facilities throughout the United States. Its operations are structured across three primary segments:...
How the Company Makes Money
AMN primarily makes money by matching healthcare providers with healthcare facilities and charging fees for those services, with revenue largely tied to the volume of clinician placements, bill rates, and assignment duration. 1) Nurse and allied ...

AMN Healthcare Services Earnings Call Summary

Earnings Call Date:Aug 06, 2026
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call presented multiple strong operational and financial highlights — revenue beat, sizable adjusted EBITDA and EPS improvement, robust cash balance, low leverage, strong Nurse & Allied performance, accelerated travel and allied volumes, and meaningful product adoption and search momentum. Several targeted acquisitions and improved operational automation/AI capabilities support longer-term growth. Offsetting these positives are notable near-term headwinds: Technology & Workforce Solutions and language services revenue declines and pricing pressure, a weaker locum/physician segment, and the fact that the Q2 outperformance was partly driven by nonrecurring items that will not repeat in Q3. Management provided conservative Q3 guidance reflecting normalization. Overall, the company appears well-positioned financially and operationally, with manageable short-term challenges and a constructive outlook into 2027.
Positive Updates
Consolidated Revenue Beat
Second quarter consolidated revenue of $673 million, which was 6% above the high end of guidance and grew 2% year-over-year.
Negative Updates
Technology & Workforce Solutions Revenue Decline
TWS revenue was $87 million, down 15% year-over-year (down 11% ex-SmartSquare divestiture); segment gross margin 48.6% declined sequentially and year-over-year.
Read all updates
Q2-2026 Updates
Negative
Consolidated Revenue Beat
Second quarter consolidated revenue of $673 million, which was 6% above the high end of guidance and grew 2% year-over-year.
Read all positive updates
Company Guidance
Management guided third-quarter consolidated revenue of $640–$655 million, gross margin of 27.0–27.5%, reported SG&A of 22.0–22.5% of revenue, operating margin of 0.2–0.8% and adjusted EBITDA margin of 6.5–7.0%; segment guidance included Nurse & Allied revenue growth of 9–11% year‑over‑year (with travel nurse and allied volume each expected to be better than +10% YoY), Physician & Leadership revenue down 5–7% YoY, and Technology & Workforce Solutions revenue down 11–13% YoY. The guide embeds roughly $7–8 million of strike‑related revenue for Q3, and management expects to exit the quarter with at least $225 million of cash (assuming remaining client deposits are repaid), with total debt of $750 million and covenant leverage of ~1.5x; modest share repurchases to offset dilution were also indicated.

AMN Healthcare Services Financial Statement Overview

Summary
Financials are stabilizing after a weak period: TTM shows a sharp revenue rebound (+44.1%) and a return to positive profitability (~3.1% net margin), with solid operating/free cash flow generation (OCF ~$471M; FCF ~$455M). Offsetting this, profitability remains well below prior-cycle peaks and results have been volatile over 2023–2025; debt is still sizable even as leverage has improved versus prior years.
Income Statement
54
Neutral
Balance Sheet
56
Neutral
Cash Flow
62
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.43B2.73B2.98B3.79B5.24B3.98B
Gross Profit954.26M774.06M919.38M1.25B1.72B1.31B
EBITDA346.43M101.13M71.11M499.36M784.21M581.70M
Net Income104.92M-95.70M-146.98M210.68M444.05M327.39M
Balance Sheet
Total Assets2.36B2.09B2.42B2.92B2.89B3.13B
Cash, Cash Equivalents and Short-Term Investments361.84M33.97M10.65M32.94M64.52M180.93M
Total Debt775.81M803.20M1.10B1.35B860.96M867.07M
Total Liabilities1.62B1.45B1.71B2.09B1.84B1.97B
Stockholders Equity741.28M642.11M706.62M831.26M1.04B1.16B
Cash Flow
Free Cash Flow439.13M233.83M239.53M268.48M572.81M251.69M
Operating Cash Flow470.76M269.46M320.42M372.17M653.73M305.36M
Investing Cash Flow31.23M4.30M-79.94M-412.49M-170.71M-107.40M
Financing Cash Flow-183.96M-295.89M-259.45M10.73M-591.87M-34.90M

AMN Healthcare Services Technical Analysis

Technical Analysis Sentiment
Positive
Last Price33.91
Price Trends
50DMA
35.20
Positive
100DMA
33.86
Positive
200DMA
27.23
Positive
Market Momentum
MACD
1.54
Negative
RSI
78.66
Negative
STOCH
88.38
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMN, the sentiment is Positive. The current price of 33.91 is below the 20-day moving average (MA) of 36.79, below the 50-day MA of 35.20, and above the 200-day MA of 27.23, indicating a bullish trend. The MACD of 1.54 indicates Negative momentum. The RSI at 78.66 is Negative, neither overbought nor oversold. The STOCH value of 88.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AMN.

AMN Healthcare Services Risk Analysis

AMN Healthcare Services disclosed 29 risk factors in its most recent earnings report. AMN Healthcare Services reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

AMN Healthcare Services Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
82
Outperform
$2.15B20.789.57%―15.88%25.01%
77
Outperform
$1.45B12.4324.12%6.27%5.22%1109.87%
71
Outperform
$2.28B13.3119.89%―0.51%63.71%
70
Outperform
$2.72B9.61150.20%―19.52%1337.90%
62
Neutral
$1.45B44.139.51%―37.90%15.84%
53
Neutral
$1.57B15.4115.31%4.95%23.99%―
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AMN
AMN Healthcare Services
41.62
21.13
103.12%
ADUS
Addus Homecare
118.03
-3.47
-2.86%
HCSG
Healthcare Services
21.50
2.65
14.06%
MD
Pediatrix Medical Group
28.08
10.96
64.02%
PNTG
Pennant Group
41.48
16.50
66.05%
AVAH
Aveanna Healthcare Holdings
12.75
3.27
34.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 07, 2026